Xiangxue Pharmaceutical (300147) - Total Liabilities
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has total liabilities worth CN¥6.75 Billion CNY (≈ $987.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Xiangxue Pharmaceutical to track the company's year-over-year net asset growth rate.
Xiangxue Pharmaceutical - Total Liabilities Trend (2007–2025)
This chart illustrates how Xiangxue Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Xiangxue Pharmaceutical to measure how efficiently the company converts operating cash flow to free cash.
Xiangxue Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Xiangxue Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southern California Bancorp Common Stock
NASDAQ:BCAL
|
USA | $3.47 Billion |
|
Shenzhen Textile Holdings Co Ltd
SHE:000045
|
China | CN¥1.17 Billion |
|
Lotte Tour Dev
KO:032350
|
Korea | ₩1.80 Trillion |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
China | CN¥2.03 Billion |
|
Liberty Broadband Srs A
NASDAQ:LBRDA
|
USA | $3.95 Billion |
|
AGF Management Limited
F:A3J
|
Germany | €504.67 Million |
|
VGI Public Company Limited
BK:VGI
|
Thailand | ฿3.49 Billion |
|
Hanilcmt Co Ltd
KO:300720
|
Korea | ₩1.14 Trillion |
Liability Composition Analysis (2007–2025)
This chart breaks down Xiangxue Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Xiangxue Pharmaceutical (300147) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -14.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xiangxue Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xiangxue Pharmaceutical (2007–2025)
The table below shows the annual total liabilities of Xiangxue Pharmaceutical from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.70 Billion ≈ $980.59 Million |
+10.59% |
| 2024-12-31 | CN¥6.06 Billion ≈ $886.71 Million |
+1.54% |
| 2023-12-31 | CN¥5.97 Billion ≈ $873.22 Million |
-8.68% |
| 2022-12-31 | CN¥6.53 Billion ≈ $956.25 Million |
-14.27% |
| 2021-12-31 | CN¥7.62 Billion ≈ $1.12 Billion |
+37.97% |
| 2020-12-31 | CN¥5.53 Billion ≈ $808.50 Million |
+27.01% |
| 2019-12-31 | CN¥4.35 Billion ≈ $636.54 Million |
-5.71% |
| 2018-12-31 | CN¥4.61 Billion ≈ $675.08 Million |
-16.98% |
| 2017-12-31 | CN¥5.56 Billion ≈ $813.16 Million |
+29.10% |
| 2016-12-31 | CN¥4.30 Billion ≈ $629.87 Million |
+289.18% |
| 2015-12-31 | CN¥1.11 Billion ≈ $161.85 Million |
-35.59% |
| 2014-12-31 | CN¥1.72 Billion ≈ $251.26 Million |
-2.70% |
| 2013-12-31 | CN¥1.76 Billion ≈ $258.23 Million |
+24.94% |
| 2012-12-31 | CN¥1.41 Billion ≈ $206.69 Million |
+181.28% |
| 2011-12-31 | CN¥502.16 Million ≈ $73.48 Million |
+5.49% |
| 2010-12-31 | CN¥476.01 Million ≈ $69.66 Million |
+31.97% |
| 2009-12-31 | CN¥360.69 Million ≈ $52.78 Million |
+1.62% |
| 2008-12-31 | CN¥354.94 Million ≈ $51.94 Million |
-1.95% |
| 2007-12-31 | CN¥361.98 Million ≈ $52.97 Million |
-- |
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more